Tag Archives: Novartis

Commentary: Novartis CEO: Gene therapy offers hope of cures in a treatment, but US needs new pricing, payment model

We live in an incredible era of progress in human health. Advances in cell and gene therapies are beginning to yield powerful new treatments for some of the most devastating illnesses. With many of these new therapies we are no longer combating diseases over time, but potentially curing them in a single treatment. This is… Read More »

Novartis could settle for $1B as part of federal kickback lawsuit: report

Six years after federal prosecutors first targeted Novartis for an alleged kickback scheme involving $ 10,000 dinners and fishing trips for doctors, signs pointed to the Swiss drugmaker finally having its day in court. Now, it looks like that may not happen. Novartis could be approaching a billion-dollar settlement with the U.S. government as part… Read More »

Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown

Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data. At the 48-week mark, 84.5% of Tremfya patients in a phase 3 study achieved a score of 90 on the Psoriasis Area Severity Index (PASI), a commonly used metric for measuring… Read More »